PROTACs

  • Are you building an effective protein degrader?

    Are you building an effective protein degrader?

    Read
  • Optimize the structure of your next round of PROTAC compounds by analyzing ternary binding affinities using Monolith

    Optimize the structure of your next round of PROTAC compounds by analyzing ternary binding affinities using Monolith

    Read

  • Characterizing interactions involving PROTACs or other TACs?

    NanoTemper tools can help

    Find out how
  • Understanding the nuances of targeted protein degradation59:35

    Understanding the nuances of targeted protein degradation

    Bifunctional degrader molecules (also known as PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases. The formation of a ternary complex between PROTAC, ligase, and the protein of inte

    Watch
  • Tackle the high-hanging fruits in challenging drug discovery pipelines17:10

    Tackle the high-hanging fruits in challenging drug discovery pipelines

    There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t

    Watch
  • Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Read

  • Have a question?

    Contact Specialist
  • Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay

    Sweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay

    Read
  • PROTACs: the game-changing technology that promises to tackle “undruggable” proteins

    PROTACs: the game-changing technology that promises to tackle “undruggable” proteins

    Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...

    Read
  • Targeting the SARS-CoV‑2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders

    Targeting the SARS-CoV‑2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders

    Read
  • Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA

    Targeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA

    Read
  • The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination

    The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination

    Read
  • A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer

    A cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer

    Read
  • loading
    Loading more...